BlueCrest Capital Management’s Edwards Lifesciences EW Stock Holding History

BlueCrest Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-20,163	Closed	-$1.24M	–	608
2019 Q2	$1.24M	Sell	20,163 -58,137	-74%	-$3.52M	0.09%	136
2019 Q1	$4.99M	Buy	+78,300	New	+$4.47M	0.2%	82
2018 Q4	–	Sell	-4,284	Closed	-$249K	–	1035
2018 Q3	$249K	Sell	4,284 -22,500	-84%	-$1.1M	0.01%	1139
2018 Q2	$1.3M	Sell	26,784 -399	-1%	-$18.6K	0.03%	443
2018 Q1	$1.26M	Buy	+27,183	New	+$1.18M	0.04%	417
2017 Q3	–	Sell	-34,137	Closed	-$1.34M	–	917
2017 Q2	$1.34M	Sell	34,137 -140,415	-80%	-$5.13M	0.05%	412
2017 Q1	$5.47M	Buy	+174,552	New	+$5.46M	0.26%	117
2016 Q3	–	Sell	-24,870	Closed	-$827K	–	819
2016 Q2	$827K	Buy	+24,870	New	+$851K	0.03%	402

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlueCrest Capital Management's EW Position: Q3 2019 in Review

BlueCrest Capital Management sold out of Edwards Lifesciences (EW) in Q3 2019, closing a stake of 20,163 shares — an estimated $1.24M sold.

BlueCrest Capital Management first reported a position in EW in Q2 2016 and held it in 8 quarters. The position peaked at $5.47M in Q1 2017. 965 funds tracked by Wall St. Rank hold EW as of Q3 2019.

BlueCrest Capital Management reported no remaining Edwards Lifesciences position as of Q3 2019 after selling out during the quarter.
BlueCrest Capital Management sold 20,163 Edwards Lifesciences shares in Q3 2019, an estimated $1.24M.
BlueCrest Capital Management first reported a position in Edwards Lifesciences in Q2 2016 and held it in 8 quarters.
BlueCrest Capital Management's Edwards Lifesciences position peaked at $5.47M in Q1 2017.
965 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2019.

Based on BlueCrest Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.